All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
ICML 2019 | In which patients with R/R cHL is camidanlumab tesirine most effective?
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Graham Collins from Oxford University Hospitals NHS Foundation Trust, Oxford, UK, asking: in which patients with relapsed/refractory classical Hodgkin lymphoma (cHL) is camidanlumab tesirine most effective?
Graham Collins discusses how camidanlumab tesirine was shown to be highly active in a phase I dose escalation trial, which had very high overall response rates, along with a significant toxicity profile.
In which patients with R/R cHL is camidanlumab tesirine most effective?
More about...
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
4 votes - 1 day left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox